These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29345163)

  • 1. Low dose HP-hMG in an antagonist protocol for IVF in ovulatory and anovulatory patients with high AMH.
    Sopa N; Larsen EC; Nyboe Andersen A
    Gynecol Endocrinol; 2018 Jul; 34(7):623-626. PubMed ID: 29345163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI.
    Sopa N; Larsen EC; Westring Hvidman H; Andersen AN
    Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():42-47. PubMed ID: 31009858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
    Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone.
    Nielsen AP; Korsholm AS; Lemmen JG; Sylvest R; Sopa N; Nyboe Andersen A
    Gynecol Endocrinol; 2016 Aug; 32(8):625-628. PubMed ID: 26891977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antral follicle count and serum anti Müllerian hormone level for determination of gonadotropin dosing in in-vitro fertilization: randomized trial.
    Li HWR; Ko JKY; Lee VCY; Yung SSF; Lau EYL; Yeung WSB; Ho PC; Ng EHY
    Ultrasound Obstet Gynecol; 2020 Mar; 55(3):303-309. PubMed ID: 31325336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments.
    Anckaert E; Smitz J; Schiettecatte J; Klein BM; Arce JC
    Hum Reprod; 2012 Jun; 27(6):1829-39. PubMed ID: 22473395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study.
    Tshzmachyan R; Hambartsoumian E
    J Gynecol Obstet Hum Reprod; 2020 Feb; 49(2):101643. PubMed ID: 31563697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
    Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review.
    Trew GH; Brown AP; Gillard S; Blackmore S; Clewlow C; O'Donohoe P; Wasiak R
    Reprod Biol Endocrinol; 2010 Nov; 8():137. PubMed ID: 21059191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.
    Yates AP; Rustamov O; Roberts SA; Lim HY; Pemberton PW; Smith A; Nardo LG
    Hum Reprod; 2011 Sep; 26(9):2353-62. PubMed ID: 21672928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
    Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
    Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
    Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.